Crucell corporate brochure (PDF)

40
Crucell’s commitment to the world – Taking responsibility
Performance
The P-category we call ‘Performance’ embraces four social responsibilities
that we see as being central to our core business and our mission:
innovation, saving lives, responsible supply chain management and
transparency, by which we mean the responsibility to evaluate and
report on our CSR activities in a comprehensive and systematic way.
Transparency is, of course, an overarching principle in our CSR program
and applies equally to all categories in the 4P policy framework.
We have chosen to include it in the category most closely allied with
our core business because we see transparency as a tool for strategic
decision making, as well as a key responsibility towards our
stakeholders. As a company dedicated to making a meaningful
difference to people’s lives, we want the fullest possible understanding
of our impact on society and our planet.
Under the leadership of the Performance P-owner, whose function in the
organization is Director Global Procurement, a large number of Crucell
employees have contributed to the gathering and analysis of information
relevant to the initial set of key performance indicators (KPIs), targets
and ambitions that were defined for this P-category in 2010 (see table 2).
The P-owner’s expertise in the field of Procurement was especially
valuable for developing a strategy for responsible supply chain
management, which is one of five KPIs for which we have set
particularly ambitious objectives.
Besides a responsible supply chain, the other KPIs we have selected to
measure our contribution in the Performance category are: prevention
of illness and deaths, the number of pipeline products, research and
development (R&D) expenses, animal welfare, CSR management
improvement, and transparency objectives (relating to benchmarks
such as the Dow Jones Sustainability Index, the Carbon Disclosure
Project and the Transparency Benchmark). These indicators form the
basis of the following discussion of activities and outcomes in the
Performance category during 2010.
1 Figures based on Crucell’s top 5 vaccines Quinvaxem®, Hepavax-Gene®, Epaxal®, Vivotif®
and Inflexal® V. Total 101,666,000 doses minus 2% waste (2,033,320 doses) = 99,632,680
doses sold in 2010 / 525600 minutes in 2010 = 189.5598 doses administered per minute.
2 Figure based on Crucell’s top five vaccines in terms of sales volumes:
Quinvaxem®, Hepavax-Gene®, Epaxal®, Vivotif® and Inflexal® V.
www.crucell.com
Saving lives
During 2010, Crucell delivered 105 million doses of vaccines to people
around the world, with the majority going to infants in developing
countries. Together, the vaccines we have on the market prevent
twelve major infectious diseases: childhood infections, travel and
endemic illnesses, and respiratory disease. Allowing for the fact
that some vaccines inevitably go to waste, we can estimate that
a Crucell vaccine was given to 190 individuals every minute during
2010 1 —a thought that makes us proud.
However, we believe that the best measure of our impact on global
health is not the number of doses we supply, but the number of deaths
and cases of disease we prevent each year. In other words, how many
people would have become sick or died if they had not received our
vaccine? This can be estimated by combining sales figures with data
on vaccine efficacy (how well a vaccine works), disease incidence
(the expected number of new cases in a population) and case fatality
(the death rate among infected patients).
Based on the best available evidence for these parameters, and
assuming a 2% vaccine waste rate, Crucell’s ‘top-five’ vaccines prevented
more than 3.6 million cases of infectious disease and 809,823 deaths in
2010 2 . This was similar to our health impact in 2009, when we prevented
more than 3.6 million cases of disease and over 819,000 deaths.
We did not meet our target of continuous improvement in the prevention
of illness and deaths, as overall product sales were slightly lower in
2010 than 2009. Higher sales of travel and endemic vaccines were more
than offset by lower sales of our seasonal influenza vaccine (due to the
limited availability of flu antigen and weaker overall demand) as well
as the temporary suspension of Quinvaxem® shipments, as explained
on page 46.